# A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

> **NCT04537923** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1428 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Insulin Lispro (U100)

## Key facts

- **NCT ID:** NCT04537923
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-19
- **Primary completion:** 2022-10-11
- **Final completion:** 2022-11-01
- **Target enrollment:** 1428 (ACTUAL)
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537923, "A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04537923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*